Although our ovarian cancer patient tumor analyses show a statistically significant p-STAT3 upregulation after treatment with PARPi, especially in tumor-infiltrating immune cells and CAFs, these subjects had undergone other treatments prior to PARPi therapy, which could confound the interpretations, and the sample size of paired patient tumor biopsies before and after PARPi therapies is small. This evidence concerns the gene STAT3 and ovarian carcinoma.